Furthermore, both preclinical models of NASH-induced HCC and human samples with NAFLD or NASH under immunotherapy treatment targeting PD1 exhibited an expansion of activated CD8 + PD1 + T cells within the tumor that indicated a compromised tumor immune surveillance [106]. Here, CD8A is linked to metabolic dysfunction-associated steatotic liver disease.